Glucose Tolerance Test

A glucose tolerance test (GTT) is a medical diagnostic procedure used to assess how well the body metabolizes glucose, a primary source of energy. This test involves measuring blood glucose levels after a period of fasting, followed by the ingestion of a specific amount of glucose, and subsequent blood glucose measurements over a defined time period. It is a key tool for diagnosing conditions characterized by impaired glucose regulation.

The biological basis of the GTT lies in the body’s intricate system for maintaining glucose homeostasis. After consuming carbohydrates, glucose enters the bloodstream, prompting the pancreas to release insulin. Insulin facilitates the uptake of glucose by cells for energy or storage. In a healthy individual, blood glucose levels rise moderately after glucose intake and then return to normal within a few hours as insulin effectively manages the glucose. However, in individuals with impaired glucose tolerance or diabetes, this process is disrupted, leading to abnormally high or prolonged elevated blood glucose levels. Genetic factors play a significant role in an individual’s glucose metabolism. Research indicates that fasting glucose concentrations are heritable, with estimates ranging from 25% to 40%^[1]. Genome-wide association studies (GWAS) have identified numerous genetic variants, such as those near the MTNR1B, FOXA2, and G6PC2-ABCB11loci, that influence fasting plasma glucose levels and contribute to the risk of developing type 2 diabetes^[2]. These genetic insights underscore the complex interplay between genetic predisposition and environmental factors in glucose regulation.

Clinically, the GTT is crucial for diagnosing prediabetes, type 2 diabetes, and gestational diabetes. Early identification through this test allows for timely intervention, such as lifestyle modifications or medication, which can prevent or delay the onset of full-blown diabetes and its associated complications. It also helps in monitoring the effectiveness of treatments for existing glucose-related conditions.

The social importance of the glucose tolerance test is substantial due to the global burden of diabetes. Diabetes and its complications, such as cardiovascular disease, kidney failure, and neuropathy, impose significant health and economic challenges on individuals and healthcare systems worldwide. By facilitating early diagnosis, the GTT contributes to public health efforts aimed at reducing the prevalence and impact of diabetes, improving patient outcomes, and enhancing the overall quality of life for millions.

Limitations

Genetic studies of glucose tolerance, while providing valuable insights, are subject to several limitations that influence the interpretation and generalizability of their findings. These limitations span methodological, population-specific, and etiological domains.

Methodological and Statistical Considerations

Many genetic variants identified for glucose homeostasis traits typically exhibit relatively small individual effect sizes, which necessitates the use of very large sample sizes and meta-analyses across multiple studies to achieve adequate statistical power^[3]. The accurate detection and validation of these associations rely on rigorous statistical methodologies, including robust procedures for controlling the false discovery rate and careful estimation of significance thresholds in genome-wide association scans ^[4]. Furthermore, the importance of independent replication cohorts cannot be overstated, as they are critical for validating initial findings, confirming their robustness, and mitigating the risk of inflated effect sizes or spurious associations that might arise from initial discovery efforts ^[5].

Population Diversity and Generalizability

A significant limitation in the genetic understanding of glucose tolerance is the historical overrepresentation of populations of European origin in genome-wide association studies^[6]. This imbalance raises substantial concerns about the generalizability of findings, as the prevalence of type 2 diabetes and related glycemic traits varies considerably across different ethnic groups, suggesting diverse underlying genetic architectures ^[6]. Therefore, dedicated research in ethnically diverse populations, such as Hispanic or East Asian cohorts, is crucial to identify novel genetic loci that may be unique or have different effect sizes in these groups, ensuring that genetic insights are broadly applicable and relevant to global health ^[7].

Phenotypic Nuance and Environmental Interactions

The precise characterization of glucose tolerance phenotypes presents inherent challenges, as measurement methodologies for assessing fasting glucose, for example, can vary between studies (e.g., measurements from whole blood, plasma, or serum often require specific conversion factors)^[8]. While standard adjustments for covariates such as age, sex, and body mass index are routinely applied and can enhance statistical power, a substantial portion of the phenotypic variance often remains unexplained by the currently identified genetic variants^[3]. This phenomenon, often referred to as “missing heritability,” points to the significant influence of unmeasured environmental factors, complex gene-environment interactions, and potentially the contribution of rarer genetic variants that may not be fully captured by common variant studies, highlighting ongoing knowledge gaps in the complete pathophysiological pathways ^[9].

Variants

Genetic variations play a crucial role in an individual’s glucose metabolism and predisposition to conditions like type 2 diabetes, often influencing the body’s response to glucose challenges. Several genes and their associated single nucleotide polymorphisms (SNPs) have been identified that impact fasting glucose levels, insulin secretion, and overall glucose tolerance. These variants can affect a range of biological pathways, from melatonin signaling to pancreatic beta-cell development and function.

Variants in the MTNR1Bgene, which encodes the melatonin receptor 1B, are strongly associated with altered glucose regulation. For instance, thers10830963 variant has been widely studied, with its glucose-raising allele linked to reduced beta-cell function and an increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release. This test assesses how efficiently an individual processes glucose, providing insights into both insulin secretion (beta-cell function) and insulin action (insulin sensitivity or resistance)^[10]. As a quantitative trait, glucose tolerance is fundamental to understanding the pathophysiology of metabolic conditions, including the risk and progression of type 2 diabetes^[1].

Key Variants

RS ID	Gene	Related Traits
rs7941837 rs10830962 rs7936247	SNRPGP16 - MTNR1B	metabolic syndrome glucose tolerance test HbA1c measurement
rs35247507 rs10476553	CAST	glucose tolerance test
rs9348441 rs35261542 rs7766070	CDKAL1	glucose measurement HbA1c measurement type 2 diabetes mellitus gestational diabetes diabetes mellitus, Drugs used in diabetes use measurement
rs508741 rs853774 rs853789	ABCB11	HbA1c measurement glucose tolerance test
rs35199395 rs9663238 rs4746822	HKDC1	vital capacity testosterone measurement serum alanine aminotransferase amount glucose tolerance test
rs10830963	MTNR1B	blood glucose amount HOMA-B metabolite measurement type 2 diabetes mellitus insulin measurement
rs732360 rs878521	CAMK2B	glucose tolerance test
rs1337919 rs6048209	LNCNEF	blood glucose amount glucose tolerance test
rs16922302 rs59858868	KANK1	glucose tolerance test
rs3934283 rs10974438 rs10758593	GLIS3	glucose measurement blood glucose amount glucose tolerance test

Measurement Methodologies and Derived Indices

The assessment of glucose tolerance involves standardized procedures, with common approaches including theFasting Plasma Glucose (FPG) test and the Oral Glucose Tolerance Test (OGTT) ^[8]. For FPG, glucose levels are measured from whole blood, plasma, or serum, with whole-blood readings often converted to FPG by multiplying by 1.13^[8]. The OGTT typically involves monitoring glucose and insulin levels over a period, such as two hours, after a glucose challenge^[6]. Various indices are derived from these measurements to provide more comprehensive insights, including the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR)and beta-cell function, calculated from fasting plasma glucose and insulin concentrations^[11]. Other measures include the Insulin Sensitivity Index ISI, the Disposition Index (DI), which reflects beta-cell compensation for insulin resistance, and theArea Under the Curve (AUC)for insulin levels during an OGTT^[12]. For research, quantitative traits like FPG are often statistically transformed, such as through rank-based inverse normal transformation or natural logarithm transformation, to improve statistical properties for genetic association analyses ^[8].

Clinical Classification and Diagnostic Thresholds

Results from glucose tolerance tests are critical for classifying an individual’s glycemic status and diagnosing metabolic disorders. For instance,fasting plasma glucose (FPG) is a primary criterion, with individuals exhibiting FPG levels of 7 mmol/L or higher typically excluded from non-diabetic cohorts in research, indicating a diagnostic threshold for diabetes ^[8]. In the context of pregnancy, gestational diabetes can be defined by specific glycemia thresholds, such as a plasma glucose level greater than 10.3 mmol/L one hour after a 50-gram glucose ingestion^[13]. Beyond categorical diagnoses, glucose tolerance is also understood dimensionally, as metabolic risk factors progressively worsen across the entire spectrum of non-diabetic glucose tolerance^[14]. This continuous understanding allows for the identification of individuals at increased risk for developing type 2 diabetes, even before meeting full diagnostic criteria ^[15].

Diagnosis

The diagnosis of glucose dysregulation, often assessed through a glucose tolerance test, involves a multi-faceted approach combining clinical evaluation with specific biochemical and increasingly, genetic markers. This comprehensive assessment aims to identify impaired fasting glucose, impaired glucose tolerance, and ultimately, type 2 diabetes, while also considering individual susceptibility and potential confounding factors.

Clinical Evaluation and Biochemical Assessment

The glucose tolerance test is a crucial functional diagnostic tool for evaluating a patient’s ability to metabolize glucose. Clinical evaluation, including physical examination, assesses risk factors and symptoms related to glucose homeostasis and insulin resistance. The test typically involves measuring fasting plasma glucose levels, followed by a standardized glucose load, and subsequent measurement of post-load glucose levels. These biochemical assays are fundamental for establishing diagnostic criteria for conditions such as impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), which represent stages of glucose dysregulation before the onset of type 2 diabetes. Abnormal results in these tests indicate a compromised ability to maintain normal glucose levels, reflecting underlying issues like insulin insensitivity^[10].

Genetic Predisposition and Biomarker Analysis

Beyond direct glucose measurements, an understanding of genetic factors can contribute to a more nuanced diagnosis of glucose tolerance. Genome-wide association studies (GWAS) have identified numerous genetic loci that influence fasting glucose homeostasis and impact the risk of type 2 diabetes^[10]. For instance, common genetic variations near the melatonin receptor MTNR1B have been shown to contribute to elevated plasma glucose levels and an increased risk of type 2 diabetes in various populations^[2]. Further research has identified low-frequency and rare exome chip variants, as well as novel variants in East Asian populations, that associate with fasting glucose and type 2 diabetes susceptibility^[8]. These molecular markers, while not typically used for primary diagnosis, can provide insights into an individual’s genetic predisposition and help contextualize biochemical findings, especially in cases with equivocal results or a strong family history.

Differential Diagnosis and Diagnostic Challenges

Distinguishing glucose dysregulation from other conditions or transient metabolic states is critical for accurate diagnosis. For example, conditions characterized by increased circulating insulin and insulin resistance, as noted in the context of glucose homeostasis research, need to be carefully evaluated to understand the underlying pathophysiology^[10]. Diagnostic challenges may arise from various factors, including temporary physiological stress, medication effects, or other endocrine disorders that can transiently affect glucose metabolism. Therefore, a diagnosis should not rely solely on a single abnormal test result but rather on a comprehensive assessment that integrates clinical history, repeated biochemical tests, and, where relevant, an understanding of genetic predispositions to avoid misdiagnosis and ensure appropriate management.

Biological Background

The glucose tolerance test is a diagnostic tool used to assess an individual’s ability to maintain healthy blood glucose levels, a critical process known as glucose homeostasis. This complex biological system involves a dynamic interplay between various organs, hormones, and genetic factors to ensure that glucose, the body’s primary energy source, is appropriately absorbed, produced, and utilized^[1]. Disruptions in this delicate balance can lead to impaired glucose tolerance and an increased risk of metabolic diseases like type 2 diabetes.

The Dynamic Balance of Glucose Homeostasis

Glucose homeostasis represents a tightly regulated balance between glucose absorption from the gut, its production primarily by the liver, and its utilization by both insulin-sensitive and insulin-insensitive tissues throughout the body^[1]. This intricate control relies on complex interactions between humoral (hormonal) and neural mechanisms that work in concert to regulate the precise equilibrium between glucose production and its uptake^[1]. When this system functions optimally, blood glucose levels remain within a narrow range, providing a steady energy supply while preventing harmful fluctuations. The oral glucose challenge, a component of glucose tolerance assessment, directly evaluates the body’s dynamic response to a glucose load, including the subsequent insulin responses^[16].

Molecular and Cellular Mechanisms of Glucose Regulation

At the cellular level, the regulation of glucose involves a network of critical proteins, enzymes, and receptors. For instance, the glucose-6-phosphatase catalytic subunit 2 (G6PC2) is a key enzyme whose coding variants have been shown to influence glycemic traits, defining an effector transcript at the G6PC2-ABCB11 locus^[3]. Variations within the G6PC2/ABCB11 genomic region are specifically associated with fasting glucose levels^[1]. Hormonal signaling, particularly by insulin, is central to glucose uptake and metabolism in target tissues. Additionally, the melatonin receptor 1B (MTNR1B) plays a role, with genetic variations near this receptor influencing fasting glucose levels and contributing to raised plasma glucose^[2]. Another important player is GRB10, which has a central role in regulating the function of pancreatic islets, the clusters of cells responsible for insulin production^[17].

Genetic Architecture of Glucose Tolerance

Genetic mechanisms significantly contribute to an individual’s glucose tolerance. Studies have shown that fasting glucose concentrations are heritable, with estimates ranging from 25% to 40%^[1]. Genome-wide association studies (GWAS) have identified numerous genetic variants associated with glucose homeostasis traits, including those influencing fasting plasma glucose^[10]. For example, specific genetic variations in the GIPRgene (Gastric Inhibitory Polypeptide Receptor) influence both glucose and insulin responses following an oral glucose challenge^[16]. Similarly, common variants near the MTNR1Bgene are linked to increased plasma glucose and a higher risk of type 2 diabetes, often by affecting early insulin secretion^[2]. The genetic basis of these traits can vary by ethnicity, highlighting the importance of studying diverse populations to gain comprehensive insights into glucose homeostasis^[6].

Pathophysiology of Dysregulated Glucose Metabolism

When glucose homeostasis is disrupted, it can lead to pathophysiological processes that underpin conditions like type 2 diabetes. A key mechanism is insulin resistance, where the body’s cells do not respond effectively to insulin, leading to increased circulating insulin levels and, in some cases, insensitivity to growth hormone^[10]. While insulin resistance is a significant and heritable component of type 2 diabetes susceptibility, many identified genetic factors for the disease primarily influence beta-cell function rather than insulin resistance^[6]. Beta-cell dysfunction, characterized by impaired early insulin secretion, is considered a key cause of type 2 diabetes, often exacerbated by genetic variants such as those inMTNR1B ^[18]. These homeostatic disruptions, driven by both genetic and environmental factors, collectively contribute to the pathogenesis of type 2 diabetes, emphasizing the importance of understanding the dynamic processes of glucose regulation^[1].

Pathways and Mechanisms

Hormonal Signaling and Initial Glucose Response

The body’s response to an oral glucose challenge involves rapid and coordinated hormonal signaling pathways crucial for maintaining glucose homeostasis. Upon glucose absorption from the gut, the gastric inhibitory polypeptide receptor (GIPR) is activated, influencing both glucose and insulin responses^[5]. This receptor activation triggers intracellular signaling cascades within pancreatic beta-cells, leading to enhanced insulin secretion—a vital feedback loop that facilitates glucose uptake by peripheral tissues^[5]. Concurrently, the melatonin receptor MTNR1B also plays a role, with genetic variations near this receptor contributing to raised plasma glucose levels and influencing fasting glucose, suggesting its involvement in circadian regulation of glucose metabolism^[2].

Hepatic Glucose Metabolism and Regulation

The liver is a central organ in glucose metabolism, dynamically balancing glucose production and utilization to maintain systemic levels^[1]. Key metabolic pathways, including gluconeogenesis and glycogenolysis, are precisely regulated to control hepatic glucose output. Genetic variations within the G6PC2/ABCB11 genomic region, particularly in G6PC2 coding variants, significantly influence fasting glucose levels and overall glycemic traits^[1]. G6PC2, as a specific glucose-6-phosphatase catalytic subunit, modulates the flux of glucose from the liver into the circulation, and its dysregulation can lead to elevated fasting glucose, impacting the body’s baseline glucose status and its subsequent response to an oral glucose load^[3].

Systemic Metabolic Integration and Crosstalk

Maintaining glucose tolerance requires complex systems-level integration and pathway crosstalk among various tissues and organs. Insulin-sensitive tissues, such as muscle and adipose tissue, are critical for glucose utilization, and their ability to respond effectively to insulin determines the rate of glucose clearance from the bloodstream^[1]. Insulin resistance, characterized by diminished responsiveness of these tissues to insulin, represents a significant breakdown in this integration, leading to higher glucose levels observed during an oral glucose tolerance test^[10]. Hierarchical regulation, involving coordinated actions of hormones like insulin and GIP across different cell types, ensures that glucose uptake, storage, and production are precisely managed, contributing to the emergent property of stable blood glucose levels^[1].

Genetic and Regulatory Mechanisms of Glucose Homeostasis

Genetic regulation profoundly shapes an individual’s glucose tolerance profile, with numerous loci identified through genome-wide association studies (GWAS) influencing fasting plasma glucose and 2-hour post-challenge glucose levels^[10]. These genetic variants can impact gene regulation, leading to altered expression of key enzymes or receptors, or affect protein modification and post-translational regulation ^[2]. For instance, specific variants in MTNR1B and GIPR demonstrably influence glucose and insulin responses, highlighting how subtle genetic differences can alter allosteric control and the overall efficiency of metabolic flux and signaling cascades^[19].

Pathway Dysregulation and Type 2 Diabetes Risk

Dysregulation within these intricate glucose metabolic and signaling pathways is a critical mechanism in the development of impaired glucose tolerance and the increased risk for type 2 diabetes (T2D). Genetic variants near MTNR1B, for example, are directly linked to raised plasma glucose and a heightened risk of T2D among various populations^[2]. Initially, compensatory mechanisms, such as increased insulin secretion by pancreatic beta-cells, may attempt to overcome early insulin resistance and maintain normoglycemia^[10]. However, the failure of these compensatory responses leads to sustained hyperglycemia, signifying a progression towards overt T2D and underscoring the importance of these pathways as potential therapeutic targets ^[10].

Clinical Relevance

The glucose tolerance test is a cornerstone in the assessment of metabolic health, offering critical insights into an individual’s ability to regulate blood glucose levels. Its clinical relevance spans diagnostic applications, risk stratification, prognostic evaluation, and informing personalized treatment and prevention strategies, particularly concerning type 2 diabetes (T2D) and related metabolic disorders. Genetic research, often leveraging data from these tests, has further deepened the understanding of glucose homeostasis and disease pathophysiology.

Diagnostic Utility and Risk Stratification

The glucose tolerance test serves as a crucial diagnostic tool for identifying impaired glucose tolerance (IGT) and overt type 2 diabetes, enabling early detection and intervention. By measuring fasting plasma glucose and subsequent glucose levels at specified intervals after an oral glucose challenge, the test provides a comprehensive picture of an individual’s glycemic control and insulin response^[5]. This detailed assessment allows clinicians to identify individuals who may not meet the criteria for diabetes but exhibit dysregulated glucose metabolism, placing them at a higher risk of progressing to T2D^[10]. Furthermore, the identification of genetic variants influencing fasting glycemic traits, such as those near the MTNR1B, G6PC2, and FOXA2 loci, enhances the precision of risk stratification. These genetic insights, combined with glucose tolerance test results, contribute to a more personalized approach in identifying high-risk individuals and tailoring prevention strategies, including intensive lifestyle modifications, to reduce the incidence of T2D^[2].

Prognostic Value and Disease Progression

The prognostic value of the glucose tolerance test extends beyond immediate diagnosis, providing essential information about an individual’s long-term metabolic outlook and the potential for disease progression. Abnormal glucose tolerance, even when not meeting the threshold for diabetes, is a significant predictor for the future development of type 2 diabetes and its associated microvascular and macrovascular complications^[10]. Research indicates that specific genetic variations, such as those in GIPR, influence glucose and insulin responses to an oral glucose challenge in non-diabetic individuals, underscoring a genetic predisposition to future metabolic dysfunction^[5]. Therefore, ongoing monitoring of glycemic traits through glucose tolerance assessments can help anticipate disease progression, allowing for timely and proactive management. The heritable nature of fasting glucose concentrations further emphasizes the importance of these tests in understanding the genetic contributions to T2D pathophysiology and predicting an individual’s disease trajectory^[1].

Genetic Contributions to Glucose Homeostasis and Treatment Implications

Advances in genome-wide association studies have elucidated the complex genetic architecture underlying glucose homeostasis, offering new avenues for personalized medicine and targeted interventions. Genetic variants located near genes such as MTNR1B, GIPR, G6PC2, and FOXA2 have been consistently linked to variations in fasting glucose levels and the dynamic glucose and insulin responses observed during an oral glucose challenge^[2]. These genetic discoveries provide crucial insights into the pathophysiological mechanisms of type 2 diabetes, including factors contributing to insulin resistance and impaired insulin secretion^[10]. By integrating these genetic insights with the detailed phenotypic data obtained from glucose tolerance tests, clinicians can better understand an individual’s unique metabolic profile. This comprehensive understanding supports the selection of more effective, personalized treatment strategies and the development of tailored prevention programs, ultimately optimizing patient care by addressing specific genetic predispositions^[20].

Frequently Asked Questions About Glucose Tolerance Test

These questions address the most important and specific aspects of glucose tolerance test based on current genetic research.

---

1. My parents both have diabetes; am I destined to get it too?

Yes, genetics plays a significant role in your risk. Research shows that fasting glucose levels, a key indicator, are 25% to 40% heritable. While you inherit a predisposition, it doesn’t mean it’s inevitable; lifestyle choices can greatly influence whether that genetic risk translates into developing diabetes.

2. Why can my friend eat anything but my blood sugar still spikes easily?

It’s often due to individual genetic differences in how your body processes sugar. Even if you eat similarly, variants in genes like MTNR1B or FOXA2can affect how your pancreas releases insulin or how your cells respond to glucose, making some people more susceptible to blood sugar spikes than others.

3. I’m Hispanic; does my background increase my blood sugar risk?

Yes, your ethnic background can influence your risk. Genetic studies have historically focused on European populations, but research highlights that the prevalence of diabetes and underlying genetic architectures differ across ethnic groups, including Hispanic populations. This means you might have unique genetic risk factors that need specific attention.

4. Can I really beat my family history of diabetes with lifestyle changes?

Absolutely, lifestyle changes are powerful. While genetic factors contribute significantly to glucose regulation, they interact with environmental factors. Even with a strong family history, adopting healthy habits like diet and exercise can profoundly impact your glucose metabolism and often prevent or delay the onset of conditions like type 2 diabetes.

5. Why should I bother with a GTT if I feel perfectly healthy?

Because genetic predispositions can mean your body isn’t metabolizing glucose as efficiently as it should, even without symptoms. The GTT can detect “prediabetes” or early type 2 diabetes, allowing for timely intervention through lifestyle changes or medication. Catching it early can prevent serious complications down the line.

6. Why doesn’t healthy eating always fix my blood sugar issues?

While diet is crucial, genetics plays a complex role. Some of your blood sugar regulation is influenced by genes, and even with currently identified genetic variants, a significant portion of individual differences remains unexplained. This “missing heritability” points to other factors like unmeasured environmental influences, gene-environment interactions, or rarer genetic variants that might be impacting your response.

7. My sibling is healthy; why am I worried about my blood sugar?

Even within families, genetic variations can lead to different susceptibilities. While you share many genes, subtle differences in variants influencing glucose metabolism—like those nearG6PC2-ABCB11—can mean one sibling has a more efficient system for handling glucose than another, even with similar lifestyles.

8. Would a DNA test tell me if I’m at high risk for diabetes?

Yes, genetic tests can identify specific variants known to influence fasting glucose levels and increase the risk for type 2 diabetes. While these tests offer valuable insights into your genetic predisposition, they are typically used in conjunction with clinical tests like the GTT to provide a comprehensive picture of your current glucose regulation.

9. Does stress actually make my blood sugar worse, beyond just food?

Yes, stress can impact your blood sugar. While the article doesn’t detail stress-specific genetic links, it acknowledges that “unmeasured environmental factors” and complex gene-environment interactions significantly influence glucose regulation. Stress can physiologically impact hormones that affect blood sugar, and this interaction can be more pronounced in individuals with certain genetic predispositions.

10. If my GTT is normal now, am I safe from future diabetes?

A normal GTT is great news, but it doesn’t guarantee future immunity, especially if you have genetic predispositions. Your genetic makeup, with variants influencing glucose metabolism, still contributes to your long-term risk. Regular monitoring and maintaining a healthy lifestyle remain crucial, as these factors interact over time to determine your overall risk.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Chen WM, et al. “Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels.”J Clin Invest, 2008.

[2] Chambers JC, et al. “Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians.”Diabetes, 2009.

[3] Mahajan A, et al. “Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus.” PLoS Genet, 2015.

[4] Xing, C. “A weighted false discovery rate control procedure reveals alleles at FOXA2 that influence fasting glucose levels.”Am J Hum Genet, vol. 86, no. 3, 2010, pp. 440–446.

[5] Saxena R, et al. “Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge.”Nat Genet, 2010.

[6] Palmer, N. D., et al. “Genetic Variants Associated With Quantitative Glucose Homeostasis Traits Translate to Type 2 Diabetes in Mexican Americans: The GUARDIAN (Genetics Underlying Diabetes in Hispanics) Consortium.”Diabetes, 2015. PMID: 25524916.

[7] Comuzzie, A. G. “Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population.”PLoS One, 2012. PMID: 23251661.

[8] Hwang JY, et al. “Genome-wide association meta-analysis identifies novel variants associated with fasting plasma glucose in East Asians.”Diabetes, 2014.

[9] Wessel J, et al. “Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility.”Nat Commun, 2015.

[10] Dupuis J, et al. “New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.”Nat Genet, 2010.

[11] Matthews, D. R., et al. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.”Diabetologia, 1985.

[12] Gutt, M., et al. “Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures.”Diabetes Res Clin Pract, 2000.

[13] Hayes, M. G., et al. “Identification of HKDC1 and BACE2 as genes influencing glycemic traits during pregnancy through genome-wide association studies.” Diabetes, 2013. PMID: 23903356.

[14] Meigs JB, et al. “Genome-wide association with diabetes-related traits in the Framingham Heart Study.” BMC Med Genet, 2007.

[15] Hanley, A. J., et al. “Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study.”Diabetes, 2003.

[16] Saxena, R, et al. “Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge.”Nat Genet, 2009.

[17] Prokopenko, I, et al. “A central role for GRB10 in regulation of islet function in man.” PLoS Genet, 2014.

[18] Florez, JC. “Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: Where are the insulin resistance genes?”Diabetologia, 2008.

[19] Prokopenko I, et al. “Variants in MTNR1B influence fasting glucose levels.”Nat Genet, 2009.

[20] Manning AK, et al. “A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.”Nat Genet, 2012.

[21] Chambers, J. C., et al. “Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians.”Diabetes, PMID: 19651812.

[22] Dupuis, J., et al. “New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.”Nat Genet, PMID: 20081858.

[23] Hwang, J. Y., et al. “Genome-wide association meta-analysis identifies novel variants associated with fasting plasma glucose in East Asians.”Diabetes, PMID: 25187374.

[24] Lunetta, K. L., et al. “Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study.” BMC Med Genet, 2007. PMID: 17903295.

[25] Lyssenko, V, et al. “Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion.”Nat Genet, 2009.

[26] Manning, A. K., et al. “A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.”Nat Genet, PMID: 22581228.

[27] Meigs, J. B., et al. “Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study.”Annals of Internal Medicine, 1998.

[28] Prokopenko, I., et al. “Variants in MTNR1B influence fasting glucose levels.”Nat Genet, PMID: 19060907.

[29] Rasmussen-Torvik, L. J., et al. “Fasting glucose GWAS candidate region analysis across ethnic groups in the Multiethnic Study of Atherosclerosis (MESA).”Genetic Epidemiology, vol. 36, no. 4, 2012, pp. 317-26.

[30] Rutter, M. K., et al. “Insulin Resistance, the Metabolic Syndrome, and Incident Cardiovascular Events in The Framingham Offspring Study.”Diabetes, 2005.

[31] Sabatti, C., et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nature Genetics, vol. 41, no. 1, 2009, pp. 35-46.

[32] Wessel, J., et al. “Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility.”Nat Commun, PMID: 25631608.